智通财经APP讯，君实生物(01877)发布截至2026年6月30日止6个月中期业绩，该集团取得收入人民币16.96亿元(单位下同)，同比增加45.18%;本公司拥有人应占溢利2550.1万元，同比扭亏为盈;每股盈利0.02元。
其中：(i)药品销售收入约14.07亿元，较2025年同期增加约33%，该上涨主要是由于商业化团队的销售效率提高以及更多拓益®适应症获批;(ii)与许可协议相关收入约2.54亿元;及(iii)技术服务及其他业务收入约3500万元。
于报告期内，拓益®国内销售收入约为12.99亿元，较2025年同期增加约36%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.